Radiopharm Theranostics (RADX) Short term Debt (2024 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Radiopharm Theranostics (RADX) has disclosed Short term Debt for 2 consecutive years, with $3.4 million as the latest value for Q2 2025.

• On a quarterly basis, Short term Debt fell 45.86% to $3.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $3.4 million, a 45.86% decrease, with the full-year FY2025 number at $3.4 million, down 45.86% from a year prior.
• Short term Debt was $3.4 million for Q2 2025 at Radiopharm Theranostics, down from $6.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $6.3 million in Q2 2024 to a low of $3.4 million in Q2 2025.

Peer Comparison